FENC
Fennec Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$316.28M
P/E Ratio
—
EPS
$-0.29
Beta
1.08
52W High
$10.45
52W Low
$5.65
50-Day MA
$7.75
200-Day MA
$8.03
Dividend Yield
—
Profit Margin
-16.40%
Forward P/E
35.09
PEG Ratio
1.47
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in Research Triangle Park, North Carolina.
Fundamentals
| Revenue (TTM) | $51.00M |
| Gross Profit (TTM) | $47.04M |
| EBITDA | $-5.49M |
| Operating Margin | -0.79% |
| Return on Equity | -52.70% |
| Return on Assets | -5.91% |
| Revenue/Share (TTM) | $1.69 |
| Book Value | $1.09 |
| Price-to-Book | 8.16 |
| Price-to-Sales (TTM) | 6.20 |
| EV/Revenue | 5.34 |
| EV/EBITDA | 20.27 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 72.60% |
| Shares Outstanding | $34.74M |
| Float | $14.22M |
| % Insiders | 14.43% |
| % Institutions | 54.28% |
Historical Volatility
HV 10-Day
55.30%
HV 20-Day
45.97%
HV 30-Day
101.13%
HV 60-Day
96.58%
HV Rank
93.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.67 target)
2
Strong Buy5
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026